Get the Stockscreener App
21.69
4.03%
-0.91
After Hours:
21.30
-0.39
-1.80%
Dbv Technologies Adr stock is traded at $21.69, with a volume of 173.46K.
It is down -4.03% in the last 24 hours and up +20.97% over the past month.
DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.
See More
Previous Close:
$22.60
Open:
$22.51
24h Volume:
173.46K
Relative Volume:
0.37
Market Cap:
$1.19B
Revenue:
-
Net Income/Loss:
$-102.09M
P/E Ratio:
-20.66
EPS:
-1.05
Net Cash Flow:
$-108.72M
1W Performance:
+1.07%
1M Performance:
+20.97%
6M Performance:
+121.10%
1Y Performance:
+426.66%
1-Day Range:
$20.84
$23.01
1-Week Range:
$20.25
$24.65
52-Week Range:
$3.82
$26.18
Dbv Technologies Adr Stock (DBVT) Company Profile
Name
Dbv Technologies Adr
Sector
Industry
Phone
33(0)155427878
Address
107 AVENUE DE LA REPUBLIQUE, CHATILLON
Compare DBVT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DBVT
Dbv Technologies Adr
|
21.69 | 1.24B | 0 | -102.09M | -108.72M | -1.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Dbv Technologies Adr Stock (DBVT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-15-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Guggenheim | Buy |
| May-29-25 | Resumed | Goldman | Sell |
| Jan-04-23 | Upgrade | Societe Generale | Hold → Buy |
| Dec-16-22 | Downgrade | Goldman | Neutral → Sell |
| May-10-22 | Downgrade | Goldman | Buy → Neutral |
| Sep-14-21 | Upgrade | Societe Generale | Hold → Buy |
| Jan-22-21 | Downgrade | Societe Generale | Hold → Sell |
| Nov-02-20 | Upgrade | Societe Generale | Sell → Hold |
| Aug-06-20 | Downgrade | Societe Generale | Buy → Sell |
| Aug-05-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-17-20 | Downgrade | Stifel | Buy → Hold |
| Jan-09-20 | Upgrade | Stifel | Hold → Buy |
| Dec-16-19 | Initiated | Citigroup | Buy |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Jun-17-19 | Initiated | Goldman | Buy |
| Dec-20-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-20-18 | Downgrade | BofA/Merrill | Buy → Underperform |
| Dec-20-18 | Downgrade | Jefferies | Buy → Hold |
| Dec-20-18 | Downgrade | Stifel | Buy → Hold |
| Oct-31-17 | Upgrade | Societe Generale | Sell → Hold |
| Oct-24-17 | Downgrade | Societe Generale | Buy → Sell |
| Oct-23-17 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-23-17 | Initiated | Deutsche Bank | Buy |
| Mar-16-17 | Upgrade | Societe Generale | Hold → Buy |
| Sep-26-16 | Initiated | JMP Securities | Mkt Outperform |
| Dec-03-15 | Initiated | Barclays | Overweight |
| Oct-23-15 | Initiated | BofA/Merrill | Buy |
View All
Dbv Technologies Adr Stock (DBVT) Latest News
DBV Technologies to Present Additional Data from the VITESSE Phase 3 Study of the VIASKIN® Peanut Patch in Children Ages 4-7 Years and Discuss Future of EPIT in the Treatment Landscape at AAAAI 2026 Annual Meeting - The Manila Times
DBV Technologies to Present Additional Data from the - GlobeNewswire
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit - markets.businessinsider.com
DBV Technologies (NASDAQ:DBVT) Upgraded at Wall Street Zen - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
European ADRs Inched Higher As GSK And Telefonica Jumped - Finimize
European ADRs Slip As Winners And Losers Split By Region - Finimize
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Galecto (GLTO), Roche Holding AG (OtherRHHVF) and Amgen (AMGN) - The Globe and Mail
DBV Technologies (NASDAQ:DBVT) Stock Price Passes Above 50 Day Moving Average – What’s Next? - Defense World
European ADRs Started The Week Higher In US Trading - Finimize
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing - Sahm
DBV Technologies (NASDAQ:DBVT) Shares Gap Up – Still a Buy? - Defense World
DBV Technologies S.A. - Via Ritzau
European ADRs Slipped, But Biotech Names Still Stole The Show - Finimize
DBV Technologies Announces €166.7 Million in Gross Proceeds - GlobeNewswire
DBV Technologies annonce avoir reçu un produit brut de 166,7 millions d'euros suite à l'exercice intégral des Bons de Souscription (BS) issus des ABSAs et des BS issus des PFW-BS-PFW émis dans le cadre de son financement de mars 2025 - GlobeNewswire Inc.
Worthington Steel, Immunitybio, Riot Platforms, Micron Technology And Other Big Stocks Moving Higher On Friday - Benzinga
DBV Technologies stock rating reiterated at Overweight by Cantor Fitzgerald - Investing.com
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading - MSN
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF) and Abivax SA Sponsored ADR (ABVX) - The Globe and Mail
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF - The Manila Times
European Equities Traded in the US as American Depositary Receipts Drop in Monday Trading - MSN
How M&A Unlocked A Biotech Rebound In 2025— And What Comes Next? - Sahm
The Insider Report: A Tape Fitting for the Holiday - Sahm
European ADRs Started The Week Higher, Led By Biotech - Finimize
Sidus Space, Starfighters Space And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session - Benzinga
Honeywell, Intuitive Machines And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Sahm
DBV Technologies (NASDAQ:DBVT) Shares Gap Down on Insider Selling - Defense World
H.C Wainwright and Citizens Raise PT on DBV Technologies (DBVT) Following Phase 3 VITESSE Trial Result - Finviz
Stock Market Today 21.12.2025 - ts2.tech
HC Wainwright Boosts Earnings Estimates for DBV Technologies - Defense World
DBV Technologies (NASDAQ:DBVT) Given New $45.00 Price Target at Citizens Jmp - Defense World
DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Rating of “Moderate Buy” from Analysts - Defense World
HC Wainwright Has Positive Outlook for DBVT FY2026 Earnings - Defense World
European Stocks On Wall Street Delivered Modest Moves For Investors - Finimize
Birkenstock, Insmed And Other Big Stocks Moving Lower In Thursday's Pre-Market Session - Benzinga
DBV Technologies (NASDAQ:DBVT) Sets New 12-Month High on Analyst Upgrade - Defense World
Crude Oil Rises Over 1%; General Mills Earnings Top Views - Benzinga
Dbv Technologies Adr Stock (DBVT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Dbv Technologies Adr Stock (DBVT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| EPIC Bpifrance | Member of 10% owner group |
Dec 17 '25 |
Sale |
4.85 |
2,076,990 |
10,070,232 |
8,595,472 |
| EPIC Bpifrance | Member of 10% owner group |
Dec 18 '25 |
Sale |
4.19 |
1,292,103 |
5,413,912 |
7,303,369 |
| Mohideen Pharis | Chief Medical Officer |
Nov 20 '25 |
Sale |
2.88 |
6,496 |
18,708 |
103,153 |
| Mohideen Pharis | Chief Medical Officer |
Nov 21 '25 |
Sale |
2.77 |
1,624 |
4,498 |
101,529 |
| Mohideen Pharis | Chief Medical Officer |
Jul 29 '25 |
Sale |
2.22 |
464 |
1,030 |
109,649 |
| Mohideen Pharis | Chief Medical Officer |
May 22 '25 |
Sale |
1.84 |
397 |
730 |
110,113 |
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):